Skip to content

Comparison of effects of Hydrofiber foam (Aquacell foam®) and povidone-iodine foam (Betafoam®) on diabetic foot ulcer; prospective randomized study

Comparison of effects of Hydrofiber foam (Aquacell foam®) and povidone-iodine foam (Betafoam®) on diabetic foot ulcer; prospective randomized study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0008071
Enrollment
70
Registered
2023-01-04
Start date
2022-05-02
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Beta Foam is applied to infected wounds to prevent absorption of exudate, bleeding or loss of body fluids and contamination. It contains povidone-iodine disinfectant and has antibacte

Sponsors

Catholic Kwandong University International St.Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Male and female patients aged 18 years or older 2) Patients consented to clinical plan and clinical follow-up, and who gave consent in written form approved by the Institutional Review Board 3) Patients with diabetic foot ulcers who have all of the following - Target ulcer present below the ankle (If two or more ulcer lesions exist, the largest ulcer is considered the target ulcer. If there are ulcers of the same size, the ulcer with a higher Wagner grade is considered the target ulcer.) - Wagner Grade I or II - Patients with ulcers larger than 1*1cm2 (length*width) after debridement

Exclusion criteria

Exclusion criteria: 1) Patients consented to clinical plan and clinical follow-up, and did not consent to the written approval of the Institutional Review Board 2) Pregnant or breast feeding women 3) Patients with hypersensitivity to povidone-iodine, a medical device for clinical trials 4) Hyperthyroidism patients or other thyroid dysfunction patients(nodular goiter, endemic goiter, Hashimoto's thyroiditis, etc.) or those receiving radioactive iodine treatment 5) Those who are participating in other interventional studies at the time of registration 6) Those with comorbidities that may affect wound healing; Malignant tumor, vasculitis, connective tissue disease, etc. 7) Patients with immunosuppression(chemotherapy, End-stage renal disease undergoing dialysis or requiring dialysis, patients with a history of previous renal transplantation or receiving specific immunosuppressants, etc.)

Design outcomes

Primary

MeasureTime frame
Size of the ulcer

Secondary

MeasureTime frame
Visual analog scale (VAS) for pain, Foot function index (FFI)

Countries

Korea, Republic of

Contacts

Public ContactDong Woo Shim

Catholic Kwandong University International St.Mary's Hospital

dcastle@hanmail.net+82-32-290-3931

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026